Invention Grant
- Patent Title: Multifunctional immunity-targeted micromolecule anti-cancer medicine Bestazomib (Bestazomib) and preparation method and application thereof
-
Application No.: US17267183Application Date: 2019-08-05
-
Publication No.: US12054502B2Publication Date: 2024-08-06
- Inventor: Wenfang Xu , Jian Zhang , Yuqi Jiang , Xiaobo Xu , Xiaoyang Li , Leqiao Tan , Yongxue Huang , Xuejian Wang , Zhen Zhang
- Applicant: SHANDONG HUBBLE KISEN BIOLOGICAL TECHNOLOGY CO., LTD.
- Applicant Address: CN Shandong
- Assignee: SHANDONG HUBBLE KISEN BIOLOGICAL TECHNONLOGY CO., LTD.
- Current Assignee: SHANDONG HUBBLE KISEN BIOLOGICAL TECHNONLOGY CO., LTD.
- Current Assignee Address: CN Shandong
- Agency: NKL Law
- Agent Bin Lu
- Priority: CN 1810902222.0 2018.08.09
- International Application: PCT/CN2019/099305 2019.08.05
- International Announcement: WO2020/029925A 2020.02.13
- Date entered country: 2021-02-09
- Main IPC: C07F5/02
- IPC: C07F5/02 ; A61P35/02 ; A61P35/00
Abstract:
A multifunctional immunity-targeted micromolecule anti-cancer medicine Citrate Bestazomib and preparation method and application thereof. The structure of the multifunctional immunity-targeted micromolecule anti-cancer medicine Bestazomib Citrate is shown as follows:
The multifunctional immunity-targeted micromolecule anti-cancer medicine Citrate Bestazomib has an activity-inhibiting effect on APN/CD13, also has an activity-inhibiting effect on tumor proteasome, and can be applied to the development of medicines for treating malignant tumors.
The multifunctional immunity-targeted micromolecule anti-cancer medicine Citrate Bestazomib has an activity-inhibiting effect on APN/CD13, also has an activity-inhibiting effect on tumor proteasome, and can be applied to the development of medicines for treating malignant tumors.
Public/Granted literature
Information query
